Clinical trial
Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent…
NCT00370227 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00370227 |
|---|---|
| Title | Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine |
| Official title | To Assess Safety, Reactogenicity & Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine, Co-admin With GSK Biologicals' MMRV Vaccine in Children (2nd yr of Life) Primed With the Pneumococcal Conjugate Vaccine in Study 105553. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Streptococcal |
| Intervention type | Biological |
| Interventions | 10 valent pneumococcal conjugate (vaccine) |
| Enrollment | 390 |
| Start date | Oct 1, 2006 |
| Completion | Mar 1, 2007 |
| First posted | Aug 31, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: